Product Description: Razoxane (ICRF 159) is an antiangiogenic topoisomerase II inhibitor, can be used for the research of renal cell carcinoma (RCC)[1].
Applications: Cancer-programmed cell death
Formula: C11H16N4O4
References: [1]J P Braybrooke, et al. A phase II study of Razoxane, an antiangiogenic topoisomerase II inhibitor, in renal cell cancer with assessment of potential surrogate markers of angiogenesis. Clin Cancer Res.2000; 6(12):4697-704./[2]F Wingen, et al. Antimetastatic effects of Razoxane in a rat osteosarcoma model. Clin Exp Metastasis.Jan-Mar 1987; 5(1):9-16.
CAS Number: 21416-67-1
Molecular Weight: 268.27
Compound Purity: 99.16
Research Area: Cancer
Solubility: 10 mM in DMSO
Target: Topoisomerase